Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Findit	5/7/2007 8:24:45 AM
	Read Replies (1) of 946

CTIC - CHICAGO, May 7 (Reuters) - Cell Therapeutics Inc. (CTIC.O: Quote, Profile , Research) said on Monday that U.S. regulators granted fast-track status to its experimental treatment for non-Hodgkin's lymphoma for a new form of the disease. The U.S. Food and Drug Administration gave the status, which speeds potential approval of the treatment, for pixantrone, which Cell Therapeutics is studying to treat relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). The FDA has already given the treatment fast-track status for aggressive forms of the disease. Reuters Pictures Editors Choice: Best pictures from the last 24 hours. View Slideshow © Reuters 2007. All Rights Reserved

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next